Introduction
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016
Summary
Global Markets Direct’s, ‘Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted pipeline therapeutics.
The report provides comprehensive information on the Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.
Scope
- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Overview 10
Therapeutics Development 11
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Stage of Development 11
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Therapy Area 12
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Indication 13
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Products Glance 16
Late Stage Products 16
Early Stage Products 17
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Companies 18
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Universities/Institutes 30
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Therapeutics Assessment 32
Assessment by Monotherapy/Combination Products 32
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 39
AB Science SA 39
Advenchen Laboratories, LLC 41
Amgen Inc. 42
ArQule, Inc. 43
Ascendis Pharma A/S 44
Astellas Pharma Inc. 45
AstraZeneca Plc 46
AVEO Pharmaceuticals, Inc. 47
Bayer AG 48
Boehringer Ingelheim GmbH 49
Bristol-Myers Squibb Company 50
CASI Pharmaceuticals Inc. 51
Celon Pharma Sp. z o.o. 52
Debiopharm International SA 53
Eddingpharm 54
Eisai Co., Ltd. 55
Eli Lilly and Company 57
Hutchison MediPharma Limited 58
Incyte Corporation 59
Johnson & Johnson 60
Les Laboratoires Servier SAS 61
Merck KGaA 62
Novartis AG 63
Principia Biopharma Inc. 64
Vichem Chemie Research Ltd. 65
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Drug Profiles 66
ARQ-087 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
ASP-5878 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
AV-370 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
AZD-4547 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
B-701 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
BAY-1163877 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
BMS-986036 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
CPL-043 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Debio-1347 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
E-7090 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
EDP-317 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
ENMD-2076 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
erdafitinib - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
HMPL-453 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
INCB-54828 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
infigratinib - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
lenvatinib mesylate - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
lucitanib - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
LY-2874455 - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
masitinib - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
nintedanib - Drug Profile 121
Product Description 121
Mechanism Of Action 121
R&D Progress 121
pazopanib hydrochloride - Drug Profile 130
Product Description 130
Mechanism Of Action 130
R&D Progress 130
pazopanib hydrochloride + pembrolizumab - Drug Profile 137
Product Description 137
Mechanism Of Action 137
R&D Progress 137
PRN-1371 - Drug Profile 138
Product Description 138
Mechanism Of Action 138
R&D Progress 138
Recombinant Peptide to Antagonize FGFR3 for Achondroplasia - Drug Profile 139
Product Description 139
Mechanism Of Action 139
R&D Progress 139
Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 140
Product Description 140
Mechanism Of Action 140
R&D Progress 140
Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 141
Product Description 141
Mechanism Of Action 141
R&D Progress 141
S-49076 - Drug Profile 142
Product Description 142
Mechanism Of Action 142
R&D Progress 142
Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 143
Product Description 143
Mechanism Of Action 143
R&D Progress 143
sprifermin - Drug Profile 144
Product Description 144
Mechanism Of Action 144
R&D Progress 144
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Dormant Projects 146
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Discontinued Products 151
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Featured News & Press Releases 153
Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product 153
Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 153
Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 154
Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung 156
Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland 157
Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 159
Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 159
Oct 03, 2016: AB Science has been invited at four international meetings to present new preclinical data showing neuroprotective effect of masitinib in amyotrophic lateral sclerosis (ALS) 160
Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma 162
Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016 163
Sep 29, 2016: AB Science Announces the Filing of Masitinib in the Treatment of Amyotrophic Lateral Sclerosis (ALS) to the European Medicines Agency 164
Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 165
Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association 165
Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 166
Sep 15, 2016: ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal 167
Appendix 168
Methodology 168
Coverage 168
Secondary Research 168
Primary Research 168
Expert Panel Validation 168
Contact Us 168
Disclaimer 169
Additional Details
Publisher
Global Markets Direct
Publisher Information
Reference
32495 | GMDHC0670TDB
Number of Pages
169
Report Format
Related Reports
| Title | Date Published | Price from | More Details |
|---|---|---|---|
| Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017 Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017Summar... | 13 Jun 2017 by Global Markets Direct | USD $3,500 | More Info |
| Fibroblast Activation Protein (FAP or Seprase) Inhibitors -Pipeline Insights, 2017 DelveInsight’s, “Fibroblast Activation Protein (FAP or Seprase) Inhibitors-Pipeline Insights, 2017”,... | 30 May 2017 by Delve Insight | USD $1,250 | More Info |
| Fibroblast Growth Factor (FGF) Inhibitors -Pipeline Insights, 2017 DelveInsight’s, “Fibroblast Growth Factor (FGF) Inhibitors-Pipeline Insights, 2017”, report provides... | 30 May 2017 by Delve Insight | USD $1,250 | More Info |
| Fibroblast Growth Factor 1 (FGF-1) Inhibitors -Pipeline Insights, 2017 DelveInsight’s, “Fibroblast Growth Factor 1 (FGF-1) Inhibitors-Pipeline Insights, 2017”, report prov... | 30 May 2017 by Delve Insight | USD $1,250 | More Info |
| Fibroblast Growth Factor Receptor (FGFR) Agonists -Pipeline Insights, 2017 DelveInsight’s, “Fibroblast Growth Factor Receptor (FGFR) Agonists-Pipeline Insights, 2017”, report ... | 30 May 2017 by Delve Insight | USD $1,250 | More Info |
| Fibroblast Growth Factor Receptor (FGFR) Inhibitors -Pipeline Insights, 2017 DelveInsight’s, “Fibroblast Growth Factor Receptor (FGFR) Inhibitors-Pipeline Insights, 2017”, repor... | 30 May 2017 by Delve Insight | USD $1,250 | More Info |
| Fibroblast Growth Factor Receptor 1 (FGFR1) Agonists -Pipeline Insights, 2017 DelveInsight’s, “Fibroblast Growth Factor Receptor 1 (FGFR1) Agonists-Pipeline Insights, 2017”, repo... | 30 May 2017 by Delve Insight | USD $1,250 | More Info |
| Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine ... | 16 Nov 2016 by Global Markets Direct | USD $3,500 | More Info |
| Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H2 2016 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 o... | 16 Nov 2016 by Global Markets Direct | USD $3,500 | More Info |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2016 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF... | 09 Nov 2016 by Global Markets Direct | USD $3,500 | More Info |
This report is published by Global Markets Direct
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Ordering Information
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.